[go: up one dir, main page]

WO2007150075A3 - Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone - Google Patents

Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone Download PDF

Info

Publication number
WO2007150075A3
WO2007150075A3 PCT/US2007/072054 US2007072054W WO2007150075A3 WO 2007150075 A3 WO2007150075 A3 WO 2007150075A3 US 2007072054 W US2007072054 W US 2007072054W WO 2007150075 A3 WO2007150075 A3 WO 2007150075A3
Authority
WO
WIPO (PCT)
Prior art keywords
hydrocodone
compositions
composition
component
controlled release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/072054
Other languages
French (fr)
Other versions
WO2007150075A2 (en
Inventor
Paul Stark
John Devane
Niall Fanning
Gary Liversidge
Scott Jenkins
Gurvinder Singh-Rekhi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perrigo Pharma International DAC
Original Assignee
Elan Pharma International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma International Ltd filed Critical Elan Pharma International Ltd
Priority to CA002660650A priority Critical patent/CA2660650A1/en
Priority to EP07784540A priority patent/EP2032139A4/en
Priority to AU2007260822A priority patent/AU2007260822B2/en
Priority to MX2008016115A priority patent/MX2008016115A/en
Priority to JP2009516757A priority patent/JP2009541360A/en
Publication of WO2007150075A2 publication Critical patent/WO2007150075A2/en
Publication of WO2007150075A3 publication Critical patent/WO2007150075A3/en
Priority to IL196066A priority patent/IL196066A0/en
Anticipated expiration legal-status Critical
Priority to NO20090119A priority patent/NO20090119L/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to a compositions comprising a nanoparticulate meloxicam composition in combination with a multiparticulate modified release hydrocodone composition that, upon administration to a patient, delivers a hydrocodone in a bimodal or multimodal manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component; the first component comprising a first population of hydrocodone - comprising particles and the at least one subsequent component comprising a second population of hydrocodone-comprising particles, wherein the combination of the components exhibit a bimodal or multimodal release profile. The invention also relates to a solid oral dosage form comprising such a combination composition.
PCT/US2007/072054 2006-06-23 2007-06-25 Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone Ceased WO2007150075A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002660650A CA2660650A1 (en) 2006-06-23 2007-06-25 Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
EP07784540A EP2032139A4 (en) 2006-06-23 2007-06-25 COMPOSITIONS COMPRISING NANOPARTICULAR MELOXICAM AND CONTROLLED RELEASE HYDROCODONE
AU2007260822A AU2007260822B2 (en) 2006-06-23 2007-06-25 Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
MX2008016115A MX2008016115A (en) 2006-06-23 2007-06-25 Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone.
JP2009516757A JP2009541360A (en) 2006-06-23 2007-06-25 Composition comprising nanoparticulate meloxicam and controlled release hydrocodone
IL196066A IL196066A0 (en) 2006-06-23 2008-12-18 Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
NO20090119A NO20090119L (en) 2006-06-23 2009-01-09 Composition comprising controlled release nanoparticulated meloxicam and hydrocodone

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81588406P 2006-06-23 2006-06-23
US60/815,884 2006-06-23

Publications (2)

Publication Number Publication Date
WO2007150075A2 WO2007150075A2 (en) 2007-12-27
WO2007150075A3 true WO2007150075A3 (en) 2008-04-24

Family

ID=38834447

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/072054 Ceased WO2007150075A2 (en) 2006-06-23 2007-06-25 Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone

Country Status (11)

Country Link
EP (1) EP2032139A4 (en)
JP (1) JP2009541360A (en)
KR (1) KR20090023729A (en)
CN (1) CN101484169A (en)
AU (1) AU2007260822B2 (en)
CA (1) CA2660650A1 (en)
IL (1) IL196066A0 (en)
MX (1) MX2008016115A (en)
NO (1) NO20090119L (en)
WO (1) WO2007150075A2 (en)
ZA (1) ZA200810098B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8808740B2 (en) 2010-12-22 2014-08-19 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US9149533B2 (en) 2013-02-05 2015-10-06 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9522135B2 (en) 2009-04-24 2016-12-20 Iceutica Pty Ltd. Formulation of indomethacin

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1429739A1 (en) 2001-09-21 2004-06-23 Egalet A/S Polymer release system
EP1429744A1 (en) 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
DE602004031096D1 (en) 2003-03-26 2011-03-03 Egalet As MORPHINE SYSTEM WITH CONTROLLED RELEASE
CA2687192C (en) 2007-06-04 2015-11-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
EP3167875A1 (en) 2009-05-27 2017-05-17 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate meloxicam compositions
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
EP2586429A1 (en) * 2011-10-26 2013-05-01 Freund Pharmatec Ltd. Multi-unit drug delivery device for pulsatile or sustained release
CN103070906A (en) * 2011-12-08 2013-05-01 赵联华 Quality control method of injection composition for treating orthopedic diseases
US9533050B2 (en) * 2011-12-29 2017-01-03 Laboratorios Andromaco S.A. Vaginal ring including meloxicam and an agent for modulating the release of the active principle, which can be used as a continuous-use contraceptive in women
US9549899B2 (en) 2012-07-06 2017-01-24 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
WO2021257784A1 (en) * 2020-06-18 2021-12-23 Verté Therapeutics, Llc Injectable meloxicam formulations
CN113181249B (en) * 2021-05-25 2022-06-14 重庆市畜牧科学院 Preparation method of traditional Chinese medicine sustained-release granules for resisting piglet diarrhea

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040176402A1 (en) * 2000-02-08 2004-09-09 Benjamin Oshlack Controlled-release compositions containing opioid agonist and antagonist
US20040229038A1 (en) * 2003-03-03 2004-11-18 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US20040266807A1 (en) * 1999-10-29 2004-12-30 Euro-Celtique, S.A. Controlled release hydrocodone formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS49982B (en) * 1997-09-17 2008-09-29 Euro-Celtique S.A., SYNERGISTIC ANALGETIC COMBINATION OF ANALGETIC OPIATE AND CYCLOOOXYGENASE-2 INHIBITOR
HU230454B1 (en) * 1998-11-02 2016-07-28 Alkermes Pharma Ireland Limited Multiparticulate modified release composition of methylphenidate
DE60222160T2 (en) * 2001-10-12 2008-06-12 Elan Pharma International Ltd., Athlone COMPOSITIONS COMPRISING PROPERTIES OF IMMEDIATE RELEASE AND CONTROLLED RELEASE

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266807A1 (en) * 1999-10-29 2004-12-30 Euro-Celtique, S.A. Controlled release hydrocodone formulations
US20040176402A1 (en) * 2000-02-08 2004-09-09 Benjamin Oshlack Controlled-release compositions containing opioid agonist and antagonist
US20040229038A1 (en) * 2003-03-03 2004-11-18 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9522135B2 (en) 2009-04-24 2016-12-20 Iceutica Pty Ltd. Formulation of indomethacin
US8808740B2 (en) 2010-12-22 2014-08-19 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US9393206B2 (en) 2010-12-22 2016-07-19 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US9572779B2 (en) 2010-12-22 2017-02-21 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US11911512B2 (en) 2010-12-22 2024-02-27 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US9149533B2 (en) 2013-02-05 2015-10-06 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9579389B2 (en) 2013-02-05 2017-02-28 Purdue Pharma L.P. Methods of preparing tamper resistant pharmaceutical formulations

Also Published As

Publication number Publication date
KR20090023729A (en) 2009-03-05
IL196066A0 (en) 2009-09-01
NO20090119L (en) 2009-03-20
ZA200810098B (en) 2009-12-30
EP2032139A4 (en) 2012-08-22
WO2007150075A2 (en) 2007-12-27
CA2660650A1 (en) 2007-12-27
AU2007260822B2 (en) 2012-07-05
EP2032139A2 (en) 2009-03-11
MX2008016115A (en) 2009-01-20
AU2007260822A1 (en) 2007-12-27
JP2009541360A (en) 2009-11-26
CN101484169A (en) 2009-07-15

Similar Documents

Publication Publication Date Title
WO2007150075A3 (en) Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
WO2007150074A3 (en) Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
WO2006102610A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109192A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109172A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109160A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109154A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2010003127A3 (en) Antagonists of prostaglandin d2 receptors
WO2010037059A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
WO2009145989A3 (en) Aminoalkylphenyl antagonists of prostaglandin d2 receptors
WO2007109182A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2009087634A3 (en) Methods and compositions for oral administration of insulin
WO2006002365A3 (en) Microparticles with high loadings of a bioactive agent
WO2008033351A3 (en) Multimodal abuse resistant and extended release formulations
WO2009108720A3 (en) Antagonists of prostaglandin d2 receptors
WO2007109201A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2006124047A3 (en) Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
WO2010057118A3 (en) Heterocyclic antagonists of prostaglandin d2 receptors
WO2010019239A3 (en) Pharmaceutical composition of n- [2,4-bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl] - 1, 4 - dihydro - 4 - oxoquinoline - 3 - carboxamide and administration thereof
WO2011106416A3 (en) Abuse-resistant formulations
IL196426A (en) Microparticles based on an amphiphilic copolymer, processes for the preparation thereof and pharmaceutical compositions containing the same
MY144857A (en) Phamaceutical composition comprising amlodipine and losartan
PT1827396T (en) Oral medicament for the modified release of at least one active principle, in multimicrocapsule form
WO2010066749A3 (en) Ulipristal acetate tablets
WO2006099514A3 (en) Drug delivery compositions and related methods

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780023516.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07784540

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007260822

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2660650

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007784540

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2008/016115

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 196066

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2009516757

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007260822

Country of ref document: AU

Date of ref document: 20070625

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020097001440

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: RU

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: PI0713038

Country of ref document: BR

Free format text: RETIRADO O PEDIDO POR NAO CUMPRIMENTO DA EXIGENCIA DA RPI 2149 DE 13/03/2012.